Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN046 + Regorafenib/Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade
NCT06099821Phase 2Active, not recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Oct 2023
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erfonrilimab in gastrointestinal cancer, sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Progression-Free Survival up to 24 months. Started Oct 2023; status: active, not recruiting.
02
Drugs
erfonrilimab
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on NCT06099821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06099821.